Alphatec (ATEC)
Builds spine-focused surgical implants, imaging, and procedural software for spine disorder treatment.
Something off on this page? Send us feedback.
Sells spine surgery implants and EOS imaging systems around a spine-only procedural platform. Revenue is concentrated in the U.S., with surgeon education, sales-agent coverage, regulatory clearance, reimbursement, and third-party manufacturing shaping execution.
Designs and sells technologies for surgical treatment of spine disorders, centered on spinal implants, access systems, biologics, and EOS full-body weight-bearing imaging. The portfolio also includes SafeOp neuromonitoring, EOS Insight planning and assessment software, and the broader InformatiX platform.
Commercial activity is concentrated in the United States, with international surgical implant work still early and focused on Australia, New Zealand, and Japan. Sales move through independent agents and direct representatives, while surgeon training and in-house development are anchored in Carlsbad.
Management reports the company as one operating segment, so product families are the clearest way to understand the business. Execution depends on surgeon adoption, FDA and foreign device regulation, procedure reimbursement, and outside manufacturers for implants, instruments, imaging equipment, and parts.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 5, 2026 | UBS | Reiterate | Rating: —Target: $15 | Target: $16 |
| Aug 5, 2026 | BMO Capital | Reiterate | Rating: —Target: $11 | Target: $12 |
| Jul 28, 2026 | UBS | Initiate | Rating: —Target: — | Target: $15 |
| Jul 23, 2026 | Stephens | Initiate | Rating: —Target: — | Target: $15 |
| Jul 8, 2026 | BMO Capital | Initiate | Rating: —Target: — | Target: $11 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $118.7M · Total debt $604.0M · Total assets $791.0M · Shareholders' equity −$12.1M
- Revenue
- $213.5M
- Operating income
- −$1.9M
- Net income
- −$25.8M
No dividends on record.
| Institutions | 72.93% | 112.65M shares | |
|---|---|---|---|
| 281 holders · as of Jun 30, 2026 | |||
| Insiders | 15.23% | 23.53M shares | |
| 14 holders · as of Sep 10, 2026 | |||
| Strategic holders | 6.89% | 10.65M shares | |
| 1 holder · as of Dec 10, 2025 | |||
| Other | 4.95% | 7.63M shares | |
| remainder | |||
154.45M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 7.33% | 11.33M | as of Jun 30, 2026 |
David R. PelizzonInsiderdirector | 6.98% | 10.77M | filed Jun 12, 2026 |
Squadron Capital LLCStrategic10 percent owner | 6.89% | 10.65M | filed Dec 10, 2025 |
Braidwell LPInstitution | 4.23% | 6.53M | as of Jun 30, 2026 |
American Century Companies IncInstitution | 4.22% | 6.52M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 10, 2026 | Patrick Miles | director, officer: CEO | +115,000 | $8.81 |
| Aug 5, 2026 | Tyson Eliot Marshall | officer: GENERAL COUNSEL & CORP. SEC. | −8,168 | $9.65 |
| Jun 11, 2026 | Karen K. Mcginnis | director | −6,050 | $8.01 |
| May 7, 2026 | Keith Valentine | director | +56,153 | $7.49 |
| May 8, 2026 | Keith Valentine | director | +43,847 | $7.54 |
- Medtronic
Scaled spine implants, biologics and robotic-navigation pressure
- Globus Medical
Pure-play spine and enabling-tech rival including NuVasive assets
- Johnson & Johnson
DePuy Synthes spine pressure across implants and robotics
- Orthofix Medical
Spine-focused public rival in fixation, biologics and bone growth
- Stryker
Narrower spine-tech rival after spinal-implant divestiture
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Alphatec | $10.39 | +2.16% | $1.56B | — | 20.6 | 1.9 | +15.1% |
| Medtronic | $91.36 | −0.43% | $117.44B | 22.6 | 15.2 | 3.1 | +13.7% |
| Globus Medical | $75.02 | +0.98% | $10.02B | 19.1 | 14.7 | 3.2 | +5.9% |
| Johnson & Johnson | $268.53 | −0.35% | $649.40B | 31.2 | 22.6 | 6.6 | +6.6% |
| Orthofix Medical | $9.12 | +1.85% | $361.8M | — | — | 0.4 | +5.1% |
| Stryker | $276.36 | +0.79% | $105.11B | 28.4 | 17.3 | 4.1 | +9.4% |
| Median | 25.5 | 16.2 | 3.2 | +6.6% |